Zenas BioPharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Rhea-AI Summary

Zenas BioPharma (Nasdaq: ZBIO) reported that on August 17, 2026 its Board Compensation Committee granted an aggregate of 11,000 restricted stock units (RSUs) to newly hired employees as employment inducement awards under Nasdaq Listing Rule 5635(c)(4). The RSUs were issued outside the company’s equity incentive plans under a dedicated 2026 Inducement Plan.

The RSUs vest in four equal annual installments, with 25% vesting on each of August 15, 2027, 2028, 2029 and 2030, subject to the employees’ continued service with Zenas through each vesting date. The awards are governed by the 2026 Inducement Plan and the applicable individual award agreements.

Market Context

Prior inducement-grant events were followed by 3.96% and 6.46% 24-hour gains, adding historical cont...

Analysis

Prior inducement-grant events were followed by 3.96% and 6.46% 24-hour gains, adding historical context to this 11,000-RSU award. The active S-3ASR shelf and moderate short positioning remained relevant risk factors to monitor.

Key Figures

Aggregate RSUs: 11,000 RSUs Vesting installments: 4 equal installments Annual vesting percentage: 25% +1 more

4 metrics

Aggregate RSUs 11,000 RSUs Inducement grant dated August 17, 2026

Vesting installments 4 equal installments Four-year vesting period

Annual vesting percentage 25% Each installment of the RSU award

Vesting dates August 15, 2027; August 15, 2028; August 15, 2029; August 15, 2030 RSU vesting schedule

Historical Context

5 past events · Latest: Aug 13 (Negative)

Pattern 5 events

Date	Event	Sentiment	24h Move	Catalyst
Aug 13	Q2 earnings report	Negative	-6.7%	Quarterly net loss and accelerated expenses accompanied otherwise positive pipeline and regulatory updates.
Jul 17	Employee inducement grants	Neutral	+4.0%	New-hire options and RSUs were granted under the 2026 Inducement Plan.
Jun 17	Employee inducement grants	Neutral	+6.5%	New-hire options and RSUs were granted under Nasdaq Listing Rule 5635(c)(4).
Jun 11	Investor presentation	Neutral	+11.5%	Management presentation became available at the H.C. Wainwright summit.
Jun 02	Phase 3 clinical data	Positive	+1.6%	INDIGO met its primary and key secondary endpoints in IgG4-related disease.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Pattern Detected

ZBIO showed mixed historical reactions: prior inducement-grant and presentation notices were followed by gains, while the recent earnings release was followed by a decline.

Key Terms

restricted stock units, rsus, nasdaq listing rule 5635(c)(4), inducement grant

4 terms

restricted stock units financial

"granted an aggregate of 11,000 restricted stock units of the Company’s common stock"

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

rsus financial

"The RSUs will vest in four (4) equal installments over a four-year period"

RSUs, or restricted stock units, are a form of company shares given to employees as part of their compensation. They are typically awarded with certain restrictions, such as a waiting period before they can be fully owned or sold, similar to earning a gift that becomes fully yours over time. For investors, RSUs can impact a company's stock offerings and reflect how much the company relies on stock-based incentives to attract and retain talent.

nasdaq listing rule 5635(c)(4) regulatory

"in accordance with Nasdaq Listing Rule 5635(c)(4)"

NASDAQ Listing Rule 5635(c)(4) is a rule that requires a company to get approval from its shareholders before selling a large amount of its shares, usually over 20%. This helps protect investors by making sure the company doesn't flood the market with new shares without their say, which could lower the stock's value.

inducement grant financial

"the “Inducement Grant”"

An inducement grant is a stock-based reward given to a new hire—often options or restricted shares—used as a recruiting “signing bonus” to encourage someone to join a company and stay long enough to add value. Investors care because these grants can dilute existing shareholdings, change executive incentives and increase reported compensation costs, so they signal both management priorities and potential impacts on shareholder value.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

WALTHAM, Mass., Aug. 18, 2026 (GLOBE NEWSWIRE) -- Zenas BioPharma, Inc. (“Zenas” or the “Company”) (Nasdaq: ZBIO), a clinical-stage global biopharmaceutical company committed to being a leader in the development and commercialization of transformative therapies for patients living with autoimmune and inflammatory diseases, today announced that on August 17, 2026 (the “Grant Date”), the Compensation Committee of the Company’s Board of Directors granted an aggregate of 11,000 restricted stock units of the Company’s common stock (“RSUs”) to newly hired employees of the Company as an inducement material to such employees’ entry into employment with the Company, in accordance with Nasdaq Listing Rule 5635(c)(4) (the “Inducement Grant”).

The RSUs will vest in four (4) equal installments over a four-year period, with vesting as to twenty-five percent (25%) of the RSUs subject to the award on each of August 15, 2027, August 15, 2028, August 15, 2029 and August 15, 2030. Inducement Grants are subject to the employees’ continued service with Zenas through the applicable vesting dates. The Inducement Grants were granted pursuant to, and are subject to, the terms and conditions of the Company’s 2026 Inducement Plan and the applicable award agreement.

About Zenas BioPharma, Inc.
Zenas is a clinical-stage global biopharmaceutical company focused on the development and commercialization of therapies for autoimmune diseases and inflammatory conditions. Zenas combines our experienced leadership team with a disciplined global product candidate acquisition approach to identify, acquire and develop product candidates with the potential to deliver clinically meaningful benefits to patients. Zenas is advancing two late-stage, potential franchise molecules, obexelimab and orelabrutinib. Obexelimab, Zenas’ lead product candidate, is a bifunctional monoclonal antibody designed to bind CD19 and FcγRIIb to inhibit the activity of B cells implicated in many autoimmune diseases without depleting them. Zenas believes that the unique mechanism of action of obexelimab and its self-administered, subcutaneous injection regimen may enable sustained control across multiple chronic autoimmune diseases. Orelabrutinib is a potentially best-in-class, highly selective CNS-penetrant, oral, small molecule BTK inhibitor. Orelabrutinib’s mechanism of action targets pathogenic B cells not only in the periphery but also within the CNS. Additionally, it directly modulates macrophages and microglial cells in the CNS, with the potential to address compartmentalized inflammation and disease progression in MS. Zenas’ earlier stage programs include ZB021, a novel, potentially best-in-class, oral, IL-17AA/AF inhibitor, ZB022, a preclinical, potentially best-in-class, oral, brain-penetrant, TYK2 inhibitor, and ZB014, a preclinical, half-life extended anti-CD19 and FcγRIIb monoclonal antibody. For more information about Zenas BioPharma, please visit https://zenasbio.com/ and follow us on LinkedIn.

The Zenas BioPharma word mark, logo mark, and the “lightning bolt” design are trademarks of Zenas BioPharma, Inc. or its affiliated companies. All rights reserved.

Contacts:

Investors:
Argot Partners
Zenas@argotpartners.com

Media:
Kristin Ainsworth
SVP, U.S. Commercial Strategy & Corporate Affairs
612.839.6748

FAQ

What did Zenas BioPharma (ZBIO) announce about inducement grants on August 18, 2026?

Zenas BioPharma announced inducement grants of 11,000 restricted stock units to newly hired employees. According to Zenas, these RSUs were approved on August 17, 2026 under Nasdaq Listing Rule 5635(c)(4) as part of the company’s 2026 Inducement Plan.

How many restricted stock units were granted in Zenas BioPharma’s (ZBIO) August 2026 inducement awards?

Zenas BioPharma granted an aggregate of 11,000 restricted stock units as inducement awards. According to Zenas, these RSUs are tied to new employee hires and are subject to the company’s 2026 Inducement Plan and individual award agreements.

What is the vesting schedule for the new Zenas BioPharma (ZBIO) inducement RSUs granted in August 2026?

The inducement RSUs vest in four equal annual installments over four years. According to Zenas, 25% of each award vests on August 15, 2027, 2028, 2029 and 2030, contingent on the employee’s continued service.

Under which plan were Zenas BioPharma’s (ZBIO) August 2026 inducement RSUs granted?

The August 2026 inducement RSUs were granted under Zenas BioPharma’s 2026 Inducement Plan. According to Zenas, the grants are also governed by applicable award agreements that specify terms and conditions, including vesting and service requirements.

Why were Zenas BioPharma (ZBIO) RSUs classified as inducement grants under Nasdaq Listing Rule 5635(c)(4)?

They were granted as a material inducement for new employees to join Zenas BioPharma. According to Zenas, this structure aligns with Nasdaq Listing Rule 5635(c)(4), which permits equity awards made as employment inducements outside shareholder-approved plans.

What employment condition applies to the Zenas BioPharma (ZBIO) inducement RSUs granted in August 2026?

Recipients must remain employed through each vesting date for the RSUs to vest. According to Zenas, continued service with the company is required for the 2027–2030 vesting installments under the inducement grant terms.